Welcome to Novo Nordisk in the United States

Product Patents

In accordance with 35 U.S.C. § 287(a), the following table used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product; additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.



PRODUCT

PATENT INFORMATION


RYBELSUS® (semaglutide) tablets, for oral use

8,129,343
8,536,122
9,278,123
10,086,047
10,278,923

 


ESPERCOT® (Antihemophilic Factor [recombinant], GlycoPEGylated-exei)

8,536,126
9,150,848
 


FIASP® (insulin aspart recombinant)

8,324,157
6,899,699
RE46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652

 


GLUCAGEN® (glucagon [rDNA origin])

No unexpired patents
 


LEVEMIR® (insulin detemir [rDNA origin] injection)

6,899,699
RE46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,775,953
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652

 


NORDITROPIN® (somatropin [rDNA origin] injection)

6,899,699
RE 46,363
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,616,180
9,687,611
9,861,757
D729,930
D765,833
9,775,953
10,220,155
10,357,616
10,376,652

 


NOVOEIGHT® (Antihemophilic Factor [Recombinant])

6,100,061
6,475,725
6,936,441
7,094,574
8,080,414
8,084,251
8,084,252
8,329,465
8,399,620
9,982,033


NOVOLIN® 70/30 (70% NPH, human insulin isophane suspension
[rDNA origin] and 30% human insulin, regular [rDNA origin])
 

No unexpired patents
 


NOVOLIN® N (insulin suspension isophane [rDNA origin])

No unexpired patents
 


NOVOLIN® R (insulin human [rDNA origin])

No unexpired patents
 


NOVOLOG® (insulin aspart [rDNA origin] injection)

For FLEXPEN and PENFILL presentations see respective entries below
 

No unexpired patents
 


NOVOLOG® MIX 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin])

For FLEXPEN presentation see entry below
 

No unexpired patents
 


NOVOSEVEN® RT (Coagulation Factor VIIa [Recombinant])

8,299,029
8,658,597
8,729,022


OZEMPIC® (semaglutide)

6,899,699
7,762,994
8,114,833
8,129,343
8,536,122
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE46,363
9,616,180
9,861,757
D724,721
D758,571
10,220,155
US 10,335,462
10,357,616
10,376,652

 


PRANDIMET® (repaglinide/metformin HCI)

No unexpired patents


PRANDIN® (repaglinide)

No unexpired patents


REBINYN® (Coagulation Factor IX (recombinant), glycoPEGylated)

7,138,371
7,416,858
7,473,680
8,404,809
8,632,770
8,791,070


RYZODEG®70/30 (insulin degludec and insulin aspart injection)

7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652

 


SAXENDA® (liraglutide [rDNA origin] injection)

6,268,343
8,114,833
8,846,618
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155  
10,357,616
10,376,652

 


TRESIBA® (insulin degludec injection)

7,615,532
6,899,699
7,762,994
8,579,869
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
9,775,953
RE 46,363
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652

 


TRETTEN® (Coagulation Factor XIII A-Subunit [Recombinant])

Patents pending


VAGIFEM® (estradiol vaginal tablets)

7,018,992
 


VICTOZA® (liraglutide [rDNA origin] injection)

6,268,343
8,114,833
8,846,618
9,968,659
RE41,956
7,762,994
8,579,869
9,265,893
 


XULTOPHY® 100/3.6 (insulin degludec and liraglutide injection)

6,268,343
6,899,699
7,615,532
RE46,363
8,672,898
8,684,969
8,846,618
8,920,383
8,937,042
9,108,002
9,132,239
9,457,154
9,486,588
7,762,994
8,579,869
9,687,611
9,775,953
9,616,180
9,861,757
D724,721
D734,450
D758,571
10,220,155
10,357,616
10,376,652
 

 


AUTOCOVER®

6,855,129
7,553,293
8,075,522
8,728,027
 


FLEXPEN®

RE 41,956
9,265,893
7,762,994
8,579,869


FLEXPRO®

6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D729,930
D765,833
7,762,994
8,579,869
9,775,953
9,616,180
9,861,757
10,220,155  
10,357,616
10,376,652

 

 

FLEXPRO® PENMATE®

No unexpired patents
 

 

FLEXTOUCH®

6,899,699
RE46,363
8,672,898
8,684,969
8,920,383
9,108,002
9,132,239
9,457,154
9,486,588
9,687,611
D724,721
D734,450
D758,571
7,762,994
8,579,869
9,775,953
9,616,180
9,861,757
10,220,155
10,357,616
10,376,652

 


NOVOFINE® 32G

No unexpired patents
 


NOVOFINE® PLUS 32G

No unexpired patents
 


NOVOPEN® ECHO®

6,663,602
7,241,278                                        10,245,383


NOVOTWIST®

7,654,986
8,137,325
8,579,869
D675,316
7,762,994


PENFILL®

No unexpired patents


PENFILL® Cartridge

7,762,994
8,579,869
 






© 2015 Novo Nordisk All rights reserved. 0715-00027690-1 September 2015